CD274 and liver cancer: Encouraged by the above results, we further assessed the therapeutic efficacy of sgCas9‐AdV/Gel in CT26 colon murine tumor model, which is characterized by poor response to anti‐PD‐L1 based ICB.[39] The treatment schedule was similar to those for Hepa 1‐6 liver cancer therapy, that is, only one intra‐tumoral injection of sgCas9‐AdV/Gel (Figure 5A).